All In Biotech

Drug Trial Radar · NCT06682793

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

May 22, 2025

Primary completion

Mar 31, 2029

Study completion Mar 31, 2030

Sponsor

Lead sponsor
A2 Biotherapeutics Inc.Industry
Sponsor type
Industry
First posted
Nov 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe for patients * Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment in BASECAMP-1 (NCT04981119) * Preconditioning lymphodepletion (PCLD) regimen * A2B395 Tmod CAR T cells at the assigned dose

Conditions

  • Solid Tumor, Adult
  • Colorectal Cancer
  • Non-Small Cell Lung
  • NSCLC (Non-small Cell Lung Cancer)
  • Cancer
  • Colon Cancer
  • Rectal Cancer
  • Lung Cancer
  • CRC
  • Head and Neck Squamous Cell Cancer
  • HNSCC
  • Renal Cell Carcinoma
  • RCC
  • Kidney Cancer
  • Triple Negative Breast Cancer
  • TNBC
  • Colorectal Adenocarcinoma

Interventions

  • A2B395Biological

    Allogeneic logic-gated Tmod CAR T cells

  • xT CDx with HLA-LOH assayDiagnostic test

    An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose levelTime frame: From the time of Informed consent until 24 months (2 years) post A2B395 infusion
  2. Phase 1: Recommended phase 2 dose (RP2D)Time frame: 28 days post A2B395 infusion
  3. Phase 2: The overall response rate (ORR) for patientsTime frame: 24 months post A2B395 infusion

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Mayo Arizona

    Phoenix, Arizona

  • UCSD Moores Cancer Center

    La Jolla, California

  • UCLA Medical Center

    Los Angeles, California

  • Stanford University

    Palo Alto, California

  • Mayo Clinic

    Jacksonville, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • NYU Langone Health

    New York, New York

  • The Ohio State University

    Columbus, Ohio

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • Fred Hutch Cancer Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.